Skip to content
Exclusive CEO Interviews

Press Release

Make us preferred on Google
Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

✨ Onyx Summary Perspective Therapeutics (NYSE American: CATX) reported updated interim results from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-expressing neuroendocrine tumors, showing strong tolerability with no dose-limiting toxicities and encouraging anti-tumor activity, including confirmed responses in 44% of patients with uniform

Verily Launches a New Consumer Health App, Verily Me, at HLTH USA 2025

Verily Launches a New Consumer Health App, Verily Me, at HLTH USA 2025

✨ Onyx Summary Verily announced the launch of Verily Me, a new consumer health app showcased at HLTH USA 2025, designed to integrate clinical insights, personal health data, and AI assistance to help users manage their health and close care gaps. Built on Verily’s precision health platform and linked to

Seer to Report Third Quarter 2025 Financial Results on November 6, 2025

Seer to Report Third Quarter 2025 Financial Results on November 6, 2025

✨ Onyx Summary Seer, Inc. (Nasdaq: SEER) announced it will report third quarter 2025 financial results on November 6, 2025, followed by a webcasted conference call. The update comes as Seer continues to expand adoption of its Proteograph Product Suite, reinforcing its position as a leading provider of scalable, high-precision proteomic

Avidity Biosciences to Participate in Upcoming Investor Conference

Avidity Biosciences to Participate in Upcoming Investor Conference

✨ Onyx Summary Avidity Biosciences (Nasdaq: RNA) will participate in a panel discussion at the Chardan 9th Annual Genetic Medicines Conference on October 21, 2025, in New York. The engagement underscores Avidity’s leadership in RNA therapeutics as it advances its Antibody Oligonucleotide Conjugate (AOC™) platform across clinical programs in rare

Belite Bio to Participate in the 2025 Maxim Growth Summit

Belite Bio to Participate in the 2025 Maxim Growth Summit

✨ Onyx Summary Belite Bio (NASDAQ: BLTE) will participate in the Maxim Growth Summit on October 22, 2025, with executive management available for one-on-one meetings. The appearance highlights investor outreach as the company advances Tinlarebant through late-stage studies in STGD1 (DRAGON, DRAGON II) and GA in dry AMD (PHOENIX). SAN DIEGO,

Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital

Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital

✨ Onyx Summary Keros Therapeutics announced agreements to repurchase all shares held by ADAR1 Capital Management and Pontifax Venture Capital for approximately $181 million at $17.75 per share as part of its $375 million capital return program. Following the transactions, the company plans to launch a $194 million tender offer

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

✨ Onyx Summary enGene Holdings granted inducement equity awards totaling 93,200 stock options to three new employees, with an exercise price of $3.79 per share and a four-year vesting schedule. The grants, made under Nasdaq Listing Rule 5635(c)(4), align new hires’ incentives with shareholder interests as the

Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

✨ Onyx Summary Belite Bio said China’s NMPA has accepted, with priority review, its NDA for Tinlarebant in Stargardt disease based on interim Phase 3 DRAGON results showing statistical significance on the primary endpoint. If approved, Tinlarebant would become the first therapy for Stargardt; Belite plans to report final topline

SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

✨ Onyx Summary SpyGlass Pharma reported 24-month interim results from its first-in-human trial of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), showing a 42% mean reduction in intraocular pressure and elimination of all topical medications in patients with open-angle glaucoma or ocular hypertension. The device demonstrated durable efficacy, safety, and improved

Alzheon Announces Peer-Reviewed Scientific Publication of Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in APOE4/4 Homozygous Individuals with Early Alzheimer’s Disease

Alzheon Announces Peer-Reviewed Scientific Publication of Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in APOE4/4 Homozygous Individuals with Early Alzheimer’s Disease

✨ Onyx Summary Alzheon announced the peer-reviewed publication of results from its pivotal Phase 3 APOLLOE4 trial evaluating oral valiltramiprosate (ALZ-801) in APOE4/4 homozygous individuals with early Alzheimer’s disease, showing cognitive and functional benefits in patients at the mild cognitive impairment stage, along with neuroprotective effects on brain atrophy

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal’s Sellersville, Pennsylvania Site

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal’s Sellersville, Pennsylvania Site

✨ Onyx Summary Piramal Pharma Solutions and NewAmsterdam Pharma announced a multi-million-dollar investment to establish a dedicated oral solid dosage suite at Piramal’s Sellersville, Pennsylvania site, enhancing production capacity for NewAmsterdam’s fixed-dose combination of obicetrapib and ezetimibe. The initiative expands Piramal’s integrated CDMO network, supports future commercial demand

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

✨ Onyx Summary Lexicon Pharmaceuticals presented new Phase 2 analyses for pilavapadin (LX9211) at the 19th Annual Pain Therapeutics Summit, confirming the 10 mg once-daily dose as the optimal candidate for Phase 3 development in diabetic peripheral neuropathic pain (DPNP). The findings—demonstrating validated biological activity, clinically meaningful pain reduction, and

Affinia Therapeutics to Participate in Upcoming Investor Conferences

Affinia Therapeutics to Participate in Upcoming Investor Conferences

✨ Onyx Summary Affinia Therapeutics CEO Rick Modi will participate in a panel on in vivo gene therapies for genetic cardiac diseases at Chardan’s 9th Annual Genetic Medicines Conference on Oct. 21 and hold one-on-one investor meetings at the Jefferies Global Healthcare Conference in London on Nov. 17–20. The

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

✨ Onyx Summary Rocket Pharmaceuticals announced that the U.S. FDA has accepted its resubmitted BLA for KRESLADI™ (marnetegragene autotemcel; marne-cel), an investigational gene therapy for severe Leukocyte Adhesion Deficiency-I (LAD-I), setting a PDUFA date of March 28, 2026. The filing is supported by Phase 1/2 data showing 100% survival

Verily, UCHealth, University of Colorado Anschutz, and RefinedScience launch strategic collaboration for AI-powered research and care transformation

Verily, UCHealth, University of Colorado Anschutz, and RefinedScience launch strategic collaboration for AI-powered research and care transformation

✨ Onyx Summary Verily has entered a multi-year strategic collaboration with UCHealth, the University of Colorado Anschutz, and RefinedScience to advance precision medicine through AI-driven data integration and analytics on Verily’s healthcare technology platform. The partnership will create AI-ready biomedical data pipelines, develop novel models across major therapeutic areas, and